The neuroleptic malignant syndrome: agent and host interaction
- 1 April 1986
- journal article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 73 (4) , 337-347
- https://doi.org/10.1111/j.1600-0447.1986.tb02694.x
Abstract
This review comprises an exhaustive analysis of 120 case reports of neuroleptic malignant syndrome (NMS) representing the majority of published clinical data on this syndrome. Epidemiological, clinical and biological parameters, as well as those concerning the agent and the treatment of the syndrome, are critically evaluated on the basis of this data. The rate of neuroleptic loading is shown to play a cardinal role in the development of NMS. Rechallenge and aftercare of patients who need anti-psychotic treatment after NMS are considered.Keywords
This publication has 49 references indexed in Scilit:
- Neuroleptic Malignant SyndromeNew England Journal of Medicine, 1985
- Neuroleptic malignant syndrome complicated by disseminated intravascular coagulationArchives of internal medicine (1960), 1984
- A Paradoxical Response to Chlorpromazine—A Possible Variant of the Neuroleptic Malignant SyndromeThe Journal of Clinical Pharmacology, 1983
- Neuroleptic Malignant SyndromeAnesthesia & Analgesia, 1983
- Treatment of the neuroleptic malignant syndrome with bromocriptinePublished by American Medical Association (AMA) ,1983
- Gas-producing Escherichia coli fasciitis in a patient with the neuroleptic malignant syndromeJAMA, 1983
- NEUROLEPTIC MALIGNANT SYNDROME AND MALIGNANT HYPERTHERMIAThe Lancet, 1983
- Catatonic-like syndrome during neuroleptic therapyPsychosomatics, 1982
- Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndromeArchives of internal medicine (1960), 1982
- HYPERTONIA AND MALIGNANT HYPERTHERMIA DUE TO MORPHINE AND NEUROLEPTICThe Lancet, 1981